{
    "eid": "2-s2.0-85143497788",
    "title": "Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Microbiology (medical)",
            "@code": "2726",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Booster dose",
        "CovovaxTM",
        "Novavax",
        "Omicron",
        "SARS-CoV-2",
        "Side effect"
    ],
    "authors": [
        "Sitthichai Kanokudom",
        "Jira Chansaenroj",
        "Nungruthai Suntronwong",
        "Suvichada Assawakosri",
        "Ritthideach Yorsaeng",
        "Pornjarim Nilyanimit",
        "Ratchadawan Aeemjinda",
        "Nongkanok Khanarat",
        "Preeyaporn Vichaiwattana",
        "Sirapa Klinfueng",
        "Thanunrat Thongmee",
        "Apirat Katanyutanon",
        "Wichai Thanasopon",
        "Jirawan Arayapong",
        "Withak Withaksabut",
        "Donchida Srimuan",
        "Thaksaporn Thatsanatorn",
        "Natthinee Sudhinaraset",
        "Nasamon Wanlapakorn",
        "Sittisak Honsawek",
        "Yong Poovorawan"
    ],
    "citedby-count": 6,
    "ref-count": 31,
    "ref-list": [
        "Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study",
        "Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination",
        "Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination",
        "Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages",
        "Specific anti-SARS-CoV-2 humoral and cellular immune responses after booster dose of BNT162b2 Pfizer-BioNTech mRNA-based vaccine: integrated study of adaptive immune system components",
        "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies",
        "Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization",
        "Immunogenicity following two doses of the BBIBP-CorV vaccine and a third booster dose with a viral vector and mRNA COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of the BBIBP-CorV vaccine",
        "Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico",
        "Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review",
        "Effectiveness of a fourth dose of Covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study",
        "High neutralizing antibody levels against severe acute respiratory syndrome coronavirus 2 omicron BA.1 and BA.2 After UB-612 Vaccine Booster",
        "Safety and efficacy of NVX-CoV2373 Covid-19 vaccine",
        "Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",
        "Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine",
        "Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine",
        "Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose",
        "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial",
        "Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial",
        "Immunogenicity and effectiveness of primary and booster vaccine combination strategies during periods of SARS-CoV-2 delta and omicron variants",
        "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",
        "Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant",
        "Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination",
        "Impact of the coronavirus disease 2019 (COVID-19) vaccine on asymptomatic infection among patients undergoing preprocedural COVID-19 molecular screening",
        "SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice",
        "Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa",
        "Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand",
        "Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: real-world data",
        "Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": null,
            "@id": "60029201",
            "affilname": "Chonburi Regional Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029201",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chonburi",
            "@id": "101931595",
            "affilname": "Chonburi Provincial Public Health Office",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101931595",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "101823394",
            "affilname": "Royal Society of Thailand",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101823394",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence in Clinical Virology",
        "Second Century Fund of Sitthichai Kanokudom",
        "Sirapa Klinfueng",
        "King Chulalongkorn Memorial Hospital",
        "Chulalongkorn University",
        "National Research Council of Thailand",
        "Faculty of Medicine, Chulalongkorn University",
        "Health Systems Research Institute"
    ]
}